Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 16, 2007 - Issue 5
Submit an article Journal homepage
216
Views
28
CrossRef citations to date
0
Altmetric
Editorial

Focus on acetylation: the role of histone deacetylase inhibitors in cancer therapy and beyond

Panagiotis A Konstantinopoulos University of Athens, Department of Biological Chemistry, Medical School, University of Athens, 75, M. Asias Street, GR-11527 Goudi-Athens, Greece. [email protected]; Harvard Medical School, Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
,
Michalis V Karamouzis University of Athens, Department of Biological Chemistry, Medical School, University of Athens, 75, M. Asias Street, GR-11527 Goudi-Athens, Greece. [email protected]
&
Athanasios G Papavassiliou University of Athens, Department of Biological Chemistry, Medical School, University of Athens, 75, M. Asias Street, GR-11527 Goudi-Athens, Greece. [email protected]
Pages 569-571 | Published online: 26 Apr 2007

Bibliography

  • RASHEED WK, JOHNSTONE RW, PRINCE HM: Histone deacetylase inhibitors in cancer therapy. Expert Opin. Investig. Drugs (2007) 16(5):659-678.
  • KONSTANTINOPOULOS PA, PAPAVASSILIOU AG: Multilevel modulation of the mevalonate and protein-prenylation circuitries as a novel strategy for anticancer therapy. Trends Pharmacol. Sci. (2007) 28(1):6-13.
  • MINUCCI S, NERVI C, LO COCO F, PELICCI PG: Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene (2001) 20(24):3110-3115.
  • PASQUALUCCI L, BERESCHENKO O, NIU H et al.: Molecular pathogenesis of non-Hodgkin’s lymphoma: the role of Bcl-6. Leuk. Lymphoma (2003) 44(Suppl. 3):S5-S12.
  • BOLDEN JE, PEART MJ, JOHNSTONE RW: Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. (2006) 5(9):769-784.
  • FRAGA MF, BALLESTAR E, VILLAR-GAREA A et al.: Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. (2005) 37(4):391-400.
  • INSINGA A, MONESTIROLI S, RONZONI S et al.: Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat. Med. (2005) 11(1):71-76.
  • NEBBIOSO A, CLARKE N, VOLTZ E et al.: Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat. Med. (2005) 11(1):77-84.
  • ZHANG K, DENT SY: Histone modifying enzymes and cancer: going beyond histones. J. Cell. Biochem. (2005) 96(6):1137-1148.
  • KONSTANTINOPOULOS PA, VANDOROS GP, PAPAVASSILIOU AG: FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities. Cancer Chemother. Pharmacol. (2006) 58(5):711-715.
  • KONSTANTINOPOULOS PA, PAPAVASSILIOU AG: 17-AAG: mechanisms of antitumour activity. Expert Opin. Investig. Drugs (2005) 14(12):1471-1474.
  • BUDILLON A, BRUZZESE F, DI GENNARO E, CARAGLIA M: Multiple-target drugs: inhibitors of heat shock protein 90 and of histone deacetylase. Curr. Drug Targets (2005) 6(3):337-351.
  • SAHA RN, PAHAN K: HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis. Cell Death Differ. (2006) 13(4):539-550.
  • SADRI-VAKILI G, CHA JH: Histone deacetylase inhibitors: a novel therapeutic approach to Huntington’s disease (complex mechanism of neuronal death). Curr. Alzheimer Res. (2006) 3(4):403-408.
  • MCLAUGHLIN F, LA THANGUE NB: Histone deacetylase inhibitors in psoriasis therapy. Curr. Drug Targets Inflamm. Allergy (2004) 3(2):213-219.
  • REDDY P, MAEDA Y, HOTARY K et al.: Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc. Natl. Acad. Sci. USA (2004) 101(11):3921-3926.
  • BARNES PJ: Theophylline in chronic obstructive pulmonary disease: new horizons. Proc. Am. Thorac Soc. (2005) 2(4):334-339.
  • KARAGIANNIS TC, EL-OSTA A: Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds? Leukemia (2007) 21(1):61-65.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.